RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat myeloma: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug, linvoseltamab, given alone or with another drug called carfilzomib, against standard treatments for people with multiple myeloma that has come back or stopped responding to therapy. About 915 participants who have had 1 to 3 prior treatments will be e…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New scan agent may spot myeloma earlier
Knowledge-focused Recruiting nowThis study tests whether a new radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the current standard tracer on PET/CT scans. About 60 adults with newly diagnosed or relapsed/refractory multiple myeloma will receive both tracers and have their sca…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC